Antiarrhythmic properties of some aroxyethylamine derivatives with adrenolytic activity

Pharmazie

Volumn 63, Issue 6, 2008, Pages 480-484

  Maciag D ^a   Bednarski, M ^a   Filipek, B ^a   Pociecha, T ^b   Szkaradek, N ^b   Marona, H ^b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; OXYETHYLAMINE DERIVATIVE; PIPERAZINE; PROPRANOLOL DERIVATIVE; QUINIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONARY REPERFUSION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HEART INFARCTION; HEART RATE; IN VITRO STUDY; IN VIVO STUDY; MALE; MORTALITY; NONHUMAN; RAT;

ADRENERGIC ANTAGONISTS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CORONARY DISEASE; ELECTROCARDIOGRAPHY; EPINEPHRINE; ETHYLAMINES; INJECTIONS, INTRAVENOUS; MYOCARDIAL REPERFUSION INJURY; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 46849097596     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2008.7818     Document Type: Article

References (23)

1. Bralet J, Didier JP, Moreau D, Opie LH, Rochette L (1985) Effect of α-adre-noceptor antagonists (phentolamine, nicergoline and prazosin) on reper-fusion arrhythmias and noradrenaline release in perfused rat heart. Br J Pharmacol 84: 9-18.
2. Bernauer M, Ernenputsch I (1988) Antagonistic effects of a̧-adrenoceptor blocking agents on arrhythmias, enzyme release, and myocardial necrosis in isolated rat hearts with coronary occlusion and reperfusion. Nau-nyn-Schmiedeberg's Arch Pharmacol 338: 88-95.
3. Black JW, Prichard BNC (1973) Activation and blockade of β-adrenoceptors in common cardiac disorders. Br Med Bull 29: 163-167.
4. Black JW, Stephensen JS (1962) Pharmacology of a new adrenergic beta-receptor blocking compound. Lancet 2: 311-314.
5. Brooks RR, Miller KE, Carpenter JK, Jones SM (1989) Broad sensitivity of rodent arrhythmia models to class I, II, III, and IV antiarrhythmic agents. Proc Soc Exp Biol Med 191: 201-209.
6. Curtis MJ, Macleod BA, Walker MJA (1987) Models for the study of arrhythmias in myocardial ischaemia and infarction: the use of the rat. J Mol Cell Cardiol 19: 399-419.
7. Fischer W (2002) Anticonvulsant profile and mechanism of action of pro-pranolol and its two enantiomers. Seizure 11: 285-302. 12. 20.
8. Jurczyk S, Kolaczkowski M, Maryniak E, Zajdel P, Pawlowski M, Tatarc-zynska E, Klodzinska A, Chojnacka-Wojcik E, Bojarski AJ, Charakchie-va-Minol S, Duszynska B, Nowak G, Maciag D (2004) New arylpiperazine 5-HT(lA) receptor ligands containing the pyrimido[2,1-f]purine fragment: synthesis, in vitro, and in vivo pharmacological evaluation. J Med Chem 47: 2659-2666.
9. Lamontagne D, Yamaguchi N, Nadeau R, De Champlain J, Godin D, Campeau N (1986) Effects of sotalol, (-)-propranolol and prazosin on reper-fusion-induced arrhythmias and increased cardiac norepinephrine release. Eur J Pharmacol 123: 1-10.
10. Langendorff O (1895) Untersuchungen am überlebenden Säugetierherzen. Pflugers Arch Physiol 61: 291-332.
11. Lopez-Rodríguez ML, Ayala D, Benhamü B, Morcillo MJ, Viso A (2002) Arylpiperazine derivatives acting at 5-HT1A receptors. Current Medicinal Chemistry 9: 443-469.
12. Maciag D, Filipek B, Czekaj T, Marona H, Nowak G (2003) Evaluation of some aroxyethylamine derivatives for hypotensive properties and their affinities for adrenergic receptors. Pharmazie 58: 899-905.
13. Mann WS, Sales EF, van Inwegen RG, Barrett JA, Smith RD, Wolf PS (1986) Celiprolol, a compound possessing weak alpha 2-adrenergic antagonist properties in the dog. Arch Int Pharmacodyn Ther 284: 53-71.
14. Marona H, Antkiewicz-Michaluk L (1998) Synthesis and anticonvulsant activity of 1,2-aminoalkanol derivatives. Acta Pol Pharm-Drug Res 55: 487-498.
15. Marona H, Pȩkala E, Filipek B, Macia̧g D, Szneler E (2001) Pharmacological properties of some aminoalkanolic derivatives of xanthone. Pharmazie 56: 567-572.
16. Marwood JF, Stokes GS (1986) Studies on the vasodilator actions of bu-cindolol in the rat. Clin Exp Pharmacol Physiol 13: 59-68.
17. Muramatsu I, Yamanaka K, Kigoshi S (1991) Pharmacological profile of the novel a̧-adrenoceptor antagonist KT-611 (naftopidil). Japan J Pharmacol 55: 391-398.
18. Paluchowska MH, Mokrosz MJ, Charakchieva-Minol S, Duszynska B, Koziol A, Wesolowska A, Stachowicz K, Chojnacka-Wójcik E (2003) Novel 4-alkyl-l-arylpiperazines and 1,2,3,4-tetrahydroisoquinolines containing diphenylmethylamino or diphenylmethoxy fragment with differentiated 5-HT1A/5-HT2A/D2 receptor activity. Polish Journal of Pharmacology 55: 543-552.
19. Shibata J (1973) The effects of barium on the action potential and the membrane current of sheep heart Purkinje fibers. J Pharmacol Exp Ther 185: 418
20. Schoetensack W, Bruckschen EG, Zech K (1983) Urapidil. In: Scriabine A (ed.) New Drugs Annual: Cardiovascular Drugs. Raven Press, New York, pp. 19-48.
21. Szekeres L, Papp J (1975) Experimental cardiac arrhythmias. In: Schmier J, Eichler O (eds.) Handbook of Experimental Pharmacology. Springer-Verlag, Berlin, Heidelberg, New York, pp. 131-182.
22. Von Mollendorff E, Abshagen U, Akpan W, Neugebauder G, Schroter E (1986) Clinical pharmacologic investigations with carvedilol, a new beta-blocker with direct vasodilator activity. Clin Pharmacol Ther 39:677-682.
23. Walker MJ, Curtis MJ, Hearse DJ, Campbell RW, Janse MJ, Yellon DM, Cobbe SM, Coker SJ, Harness JB, Harron DW, Higgins AJ, JuUan DG, Lab MJ, Manning AS, Northover BJ, Parratt JR, Riemersma RA, Riva E, Russel DC, Sheridan DJ, Winslow E, Woodward B (1988) The Lambeth Conventions: guidelines for the study of arrhythmias in ischemia, infarction, and reperfusion. Cardiovasc Res 22: 447-455. 15.